Tracleer is owned by Actelion.
Tracleer contains Bosentan.
Tracleer has a total of 2 drug patents out of which 0 drug patents have expired.
Tracleer was authorised for market use on 05 September, 2017.
Tracleer is available in tablet, for suspension;oral dosage forms.
The generics of Tracleer are possible to be released after 28 December, 2027.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8309126||ACTELION||Dispersible bosentan tablet|| |
(3 years from now)
|US7959945||ACTELION||Dispersible bosentan tablet|| |
(4 years from now)
|Orphan Drug Exclusivity (ODE)||Sep 5, 2024|
Market Authorisation Date: 05 September, 2017
Dosage: TABLET, FOR SUSPENSION;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic